UP!

ALNY $133.34   View long term graphs

Alnylam Pharmaceuticals
Type
Public
Traded as NASDAQ: ALNY
Industry Pharmaceutical
Founded 2002
Headquarters Cambridge, MA, USA
Key people
John Maraganore, (CEO)
Number of employees
> 500 (2017)
Website Alnylam.com

Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.

In 2002, Alnylam was founded by scientists Phillip Sharp, Paul Schimmel, David Bartel, Thomas Tuschl, and Phillip Zamore, and by investors Christoph Westphal and John Kennedy Clarke; John Maraganore was the founding CEO. The company was named after Alnilam, a star in Orion’s belt. The spelling was modified to make it unique. In 2003, the firm merged with the German pharmaceutical company, Ribopharma AG. The newly formed company also received $24.6 million in funding from private-equity firms. On February 27, 2004, Alnylam Pharmaceuticals filed for an IPO. The company raised $26 million and began trading as ALNY on the Nasdaq stock exchange.

In 2005, the company partnered with Medtronic to develop drug-device combinations to treat neurodegenerative disorders; and in 2006 with Biogen Idec to develop treatments of progressive multifocal leukoencephalopathy; In 2007, it entered into a nonexclusive alliance with Hoffmann-La Roche, in which Alnylam received $331 million in exchange for access to its technology platform. an dalso partnered with Isis Pharmaceuticals to found the company Regulus Therapeutics, focused on microRNA therapeutics.

In 2009, the company formed alliances with Cubist Pharmaceuticals and Kyowa Hakko Kirin to market a drug targeted at respiratory syncytial virus. In 2010, it expanded its previous collaboration with Medtronic to include the CHDI Foundation in its Huntington's Disease focused research . In 2011, it partnered with GlaxoSmithKline to develop RNAi technology enhancing vaccine production. The company entered into a 10-year alliance with Monsanto in 2012, to develop biotech solutions for the farming industry by developing natural molecules for crop protection. In 2012, it formed a partnership with Sanofi Genzyme to develop a treatment for transthyretin-mediated amyloidosis, a hereditary disease in Asia. In February 2013, it formed a partnership with The Medicines Company to develop a drug to treat a genetic form of high cholesterol.

In July 2013, during a Phase I trial Alnylam demonstrated statistically significant reduction of a protein called transthyretin, or TTR and demonstrated human efficacy with intravenous and subcutaneous modes of administration. In 2014, Sanofi Genzyme acquired a 12 percent stake in Alnylam and increased its rights to several of the company's drugs for $700 million. In a separate transaction Alnylam announced that it had purchased Merck & Co.'s Sirna Therapeutics, for $25 million cash and $150 million in stock. In 2015, the company had $41 million in revenue and a market cap of $5.2 billion.

In 2016, the company purchased land in Norton, Massachusetts to build a manufacturing facility.

In October 2016 the Phase III clinical trial of the company's lead product, revusiran, was halted due to increased deaths in the drug arm of the trial, and the company said it was terminating development of the compound.

In 2016, Alnylam Pharmaceuticals had 18 potential treatments in various development stages in Genetic Medicine, Cardio-Metabolic Disease and Hepatic Infectious Disease. In late 2016, the company's lead candidate in phase III studies was patisiran, a treatment targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR), in patients with familial amyloidotic polyneuropathy (FAP).

News

Alnylam Pharmaceuticals, Inc. -1.14% (healthcare)

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q4 2020 2021-02-04 Future report Set alerts
Q3 2020 2020-10-29 Future report Set alerts
Q2 2020 2020-08-06 -1.56 -1.56
Q1 2020 2020-05-06 -1.62 -1.62
Q4 2019 2020-02-06 -2.47 -2.47
Q3 2019 2019-10-31 -1.92 -1.92
Q2 2019 2019-08-06 -2.02 -2.02
Q1 2019 2019-05-01 -1.73 -1.73
Q4 2018 2019-02-07 -2.09 -2.09
Q3 2018 2018-11-07 -2.43 -2.43

Ratings

2016-07-11 Reiterated Rating Chardan Capital Buy
2016-07-10 Reiterated Rating JMP Securities Buy
2016-07-05 Reiterated Rating FBR & Co Outperform $180.00
2016-07-05 Reiterated Rating Cowen and Company Buy $150.00
2016-07-01 Reiterated Rating Needham & Company LLC Buy $152.00
2016-06-30 Reiterated Rating Jefferies Group Buy
2016-06-23 Reiterated Rating JMP Securities Buy $127.00
2016-06-13 Reiterated Rating Needham & Company LLC Buy
2016-06-12 Reiterated Rating Credit Suisse Buy
2016-06-12 Reiterated Rating Leerink Swann Buy
2016-06-12 Reiterated Rating Cowen and Company Buy
2016-06-12 Reiterated Rating Credit Suisse Group AG Buy
2016-06-10 Reiterated Rating FBR & Co. Buy
2016-06-10 Reiterated Rating FBR & Co Buy
2016-06-08 Reiterated Rating Jefferies Group Buy $119.00 to $80.00
2016-05-26 Lower Price Target Chardan Capital Buy $115.00 to $93.00
2016-05-26 Reiterated Rating Piper Jaffray Buy
2016-05-26 Reiterated Rating Piper Jaffray Cos. Buy
2016-05-22 Reiterated Rating Cowen and Company Buy
2016-05-04 Reiterated Rating Jefferies Group Buy $122.00 to $119.00
2016-05-04 Reiterated Rating Needham & Company LLC Buy
2016-05-03 Reiterated Rating Cowen and Company Buy
2016-05-03 Lower Price Target Leerink Swann Outperform $120.00 to $107.00
2016-04-29 Reiterated Rating FBR & Co. Buy
2016-04-19 Reiterated Rating Jefferies Group Buy $122.00
2016-04-17 Reiterated Rating Cowen and Company Buy
2016-04-14 Reiterated Rating Chardan Capital Buy
2016-04-04 Initiated Coverage Chardan Capital Buy $93.00
2016-03-11 Upgrade JPMorgan Chase & Co. Neutral to Overweight $111.00 to $81.00
2016-03-10 Reiterated Rating Cowen and Company Buy
2016-03-09 Lower Price Target JMP Securities Market Outperform $144.00 to $135.00
2016-03-09 Lower Price Target JPMorgan Chase & Co. Market Outperform $144.00 to $135.00
2016-02-22 Lower Price Target Goldman Sachs $107.00 to $70.00
2016-02-22 Lower Price Target Goldman Sachs Group Inc. $107.00 to $70.00
2016-02-16 Lower Price Target Leerink Swann Outperform $152.00 to $120.00
2016-02-16 Reiterated Rating FBR & Co. Outperform $180.00
2016-02-14 Reiterated Rating Piper Jaffray Overweight $184.00 to $102.00
2016-02-12 Reiterated Rating Cowen and Company Buy $150.00
2016-01-29 Reiterated Rating FBR & Co. Outperform $180.00
2016-01-28 Initiated Coverage FBR & Co. Buy
2016-01-19 Initiated Coverage Credit Suisse Outperform $154.00
2016-01-12 Reiterated Rating Cowen and Company Outperform $150.00
2016-01-05 Reiterated Rating Piper Jaffray Overweight $184.00
2015-12-13 Reiterated Rating Needham & Company LLC Buy
2015-12-07 Reiterated Rating Cowen and Company Buy $150.00
2015-12-07 Initiated Coverage Needham & Company LLC Buy
2015-11-30 Reiterated Rating Leerink Swann Outperform
2015-11-26 Downgrade S&P Equity Research Buy to Hold
2015-11-10 Boost Price Target Leerink Swann Outperform $151.00 to $152.00
2015-11-10 Boost Price Target Jefferies Group Buy $107.00 to $126.00
2015-11-08 Reiterated Rating FBR & Co. Buy $180.00
2015-11-04 Reiterated Rating Needham & Company LLC Buy $152.00
2015-10-22 Initiated Coverage Jefferies Group Buy $107.00
2015-10-13 Reiterated Rating FBR & Co. Buy $180.00
2015-09-29 Reiterated Rating Piper Jaffray Buy
2015-09-22 Reiterated Rating Piper Jaffray Buy
2015-09-15 Reiterated Rating Needham & Company LLC Buy $152.00
2015-08-31 Boost Price Target Leerink Swann Outperform $145.00 to $151.00
2015-08-31 Reiterated Rating Needham & Company LLC Buy to Buy $152.00
2015-08-31 Boost Price Target Piper Jaffray Overweight $180.00 to $184.00
2015-08-28 Reiterated Rating JMP Securities Outperform $144.00
2015-08-17 Reiterated Rating Leerink Swann Outperform $145.00
2015-08-11 Initiated Coverage FBR & Co. Outperform $180.00
2015-08-07 Reiterated Rating Needham & Company LLC Buy $152.00
2015-08-07 Downgrade JPMorgan Chase & Co. Overweight to Neutral $125.00 to $115.00
2015-07-02 Reiterated Rating Piper Jaffray Outperform $150.00 to $180.00
2015-06-24 Set Price Target Deutsche Bank Buy $155.00
2015-06-24 Set Price Target Cowen and Company Buy $150.00
2015-06-24 Reiterated Rating Canaccord Genuity Buy $160.00
2015-06-24 Reiterated Rating Needham & Company LLC Buy $152.00
2015-06-24 Set Price Target Deutsche Bank AG Buy $155.00
2015-06-15 Reiterated Rating Deutsche Bank Positive
2015-06-15 Boost Price Target Piper Jaffray Overweight $155.00 to $180.00
2015-06-14 Reiterated Rating Needham & Company LLC Buy $152.00
2015-06-12 Set Price Target Deutsche Bank Buy $155.00
2015-06-05 Reiterated Rating Canaccord Genuity Buy $160.00
2015-05-26 Reiterated Rating Canaccord Genuity Buy $160.00
2015-05-18 Set Price Target Canaccord Genuity Buy $160.00
2015-05-08 Set Price Target Needham & Company LLC Buy $152.00
2015-05-08 Set Price Target Canaccord Genuity Buy $160.00
2015-04-21 Boost Price Target Leerink Swann $145.00
2015-04-21 Boost Price Target Needham & Company LLC Buy $120.00 to $152.00
2015-04-16 Reiterated Rating Canaccord Genuity Buy $160.00
2015-03-17 Initiated Coverage Janney Montgomery Scott Buy $139.00
2015-03-03 Initiated Coverage Barclays Overweight $125.00
2015-03-03 Initiated Coverage Barclays PLC Overweight $125.00
2015-02-27 Initiated Coverage Cowen and Company Outperform $150.00
2015-02-25 Reiterated Rating Canaccord Genuity Buy $160.00
2015-02-13 Set Price Target Needham & Company LLC Buy $120.00
2015-02-08 Set Price Target Canaccord Genuity Buy $160.00
2015-01-08 Boost Price Target Deutsche Bank $155.00
2015-01-07 Initiated Coverage Canaccord Genuity Buy
2014-12-30 Initiated Coverage Goldman Sachs Neutral
2014-12-24 Boost Price Target JPMorgan Chase & Co. Overweight $90.00 to $106.00
2014-12-15 Boost Price Target Piper Jaffray Overweight $134.00 to $158.00
2014-12-12 Initiated Coverage Goldman Sachs Neutral $113.00
2014-11-17 Reiterated Needham Buy $94 to $120
2014-11-17 Boost Price Target Needham & Company LLC Buy $94.00 to $120.00
2014-09-18 Initiated Coverage Leerink Swann Outperform $103.00
2014-02-14 Reiterated Needham Buy $65 to $84
2014-02-14 Boost Price Target Needham & Company LLC Buy $65.00 to $84.00
2014-01-31 Boost Price Target JMP Securities $68.00 to $110.00
2014-01-17 Boost Price Target Deutsche Bank Buy $80.00 to $108.00
2014-01-14 Downgrade Morgan Stanley Overweight to Equal Weight $72.00 to $54.00
2014-01-13 Downgrade S&P Equity Research Neutral
2014-01-13 Reiterated Rating JMP Securities Market Perform
2013-11-11 Boost Price Target Leerink Swann Outperform $80.00 to $82.00
2013-09-24 Boost Price Target Deutsche Bank Buy $60.00 to $80.00
2013-09-24 Reiterated
2013-09-23 Upgrade Needham & Company LLC Positive $55.00 to $65.00
2013-09-23 Boost Price Target Leerink Swann Outperform $57.00 to $80.00
2013-08-09 Reiterated Needham Buy $40 to $55
2013-07-01 Reiterated Needham Buy $28 to $40
2013-02-11 Downgrade MLV & Co Buy to Hold $20 to $27.50
2012-07-16 Reiterated Needham Buy $16 to $20
2012-02-10 Reiterated JMP Securities Mkt Outperform $12 to $17
2011-12-15 Initiated JMP Securities Mkt Outperform $12
2011-10-14 Initiated Rodman & Renshaw Mkt Outperform $12
2011-05-06 Initiated MLV Capital Buy $15
2010-09-24 Reiterated Rodman & Renshaw Mkt Outperform $37 to $24
2010-05-20 Initiated ThinkEquity Buy
2009-11-24 Downgrade Roth Capital Buy to Hold $26 to $17
2009-06-10 Initiated Roth Capital Buy $26
2009-06-10 Initiated Jefferies & Co Buy $28
2009-02-25 Upgrade Needham Underperform to Hold
2008-08-20 Initiated Leerink Swann Underperform $15
2008-03-03 Downgrade Needham & Co Hold to Underperform
2016-07-11 Reiterated Rating Chardan Capital Buy
2016-07-10 Reiterated Rating JMP Securities Buy
2016-07-05 Reiterated Rating FBR & Co Outperform $180.00
2016-07-05 Reiterated Rating Cowen and Company Buy $150.00
2016-07-01 Reiterated Rating Needham & Company LLC Buy $152.00

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
SANOFI-AVENTIS 13.82%  (10554134) ALNY / KBIO / REGN / RGLS /
ALNYLAM PHARMACEUTICALS, INC. 7.89%  (6021900) ALNY / RGLS /
NOVARTIS AG 5.31%  (4051002) ALNY / IDIX /
MARAGANORE JOHN CEO 0.20%  (151297) AGIO / ALNY / BLUE / RGLS /
SHARP PHILIP A 0.18%  (140795) ALNY /
Greene Barry E President and COO 0.08%  (61968) ACOR / ALNY / KPTI / RGLS /
Reid Laurence SVP, Chief Business Officer 0.02%  (18103) ALNY /
KEATING LAURIE SVP, GC and Secretary 0.02%  (14500) ALNY /
Vaishnaw Akshay SVP, Chief Medical Officer 0.01%  (11215) ALNY /
Mason Michael VP, Finance and Treasurer 0.01%  (6352) ALNY /
BONNEY MICHAEL W 0.01%  (4000) ALNY / CBST / CELG / HQH / HQL / NPSP / SRPT /

Comments